Fibrinolytic agents and their effects on the haemostatic system

article
Kluft, C.
Fibrinolytic agents used in intravenous thrombolytic therapy of myocardial infarction also exert, at effective dosages, significant side effects on the haemostatic system outside the direct resolution of the target thrombus. The side effects of the agents streptokinase and anisoylated plasminogen-streptokinase activator complex are larger than the side effects of the more fibrin-specific agents tissue-type plasminogen activator and pro-urokinase. An important difference between the two groups of compounds is that the major plasmin inhibitor α2-antiplasmin is completely exhausted for the first two agents, but only in part of the cases for the fibrin-specific agents. The effects on various factors in the fibrinolytic cascade on the plasminogen activator, plasminogen-plasmin and fibrinogen-fibrin levels are reviewed concisely.
Chemicals/CAS: anistreplase, 81669-57-0; antiplasmin, 9049-68-7; fibrinogen, 9001-32-5; plasminogen activator, 9039-53-6; prourokinase, 82657-92-9; streptokinase, 9002-01-1; Fibrin, 9001-31-4; Fibrinogen, 9001-32-5; Fibrinolytic Agents; Plasmin, EC 3.4.21.7; Plasminogen, 9001-91-6; Tissue Plasminogen Activator, EC 3.4.21.68
Topics



















anistreplaseantiplasminfibrinogenplasminogen activatorprourokinasestreptokinasebleedingfibrinolysisheart infarctionshort surveyBlood Coagulation TestsFibrinFibrinogenFibrinolysisFibrinolytic AgentsHemostasisHumanPlasminPlasminogenTissue Plasminogen Activator
TNO Identifier
230540
Repository link
https://resolver.tno.nl/uuid:9bf38035-4ed0-478e-81b6-44c92ccac817
ISSN
00232173
Source
Klinische Wochenschrift, 66(SUPPL. 12), pp. 50-54.
Pages
50-54
Files
To receive the publication files, please send an e-mail request to TNO Repository.